Connect with us

Investing

US FDA panel votes against Merck’s chronic cough drug

Published

on

© Reuters. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo

(Reuters) – The U.S. health regulator’s advisers on Friday did not recommend Merck’s drug for the treatment of chronic cough.

The FDA panel voted 12 to 1 that the data presented does not demonstrate substantial evidence of effectiveness of the oral tablet, gefapixant, for the treatment of refractory or unexplained chronic cough.

Read the full article here

Trending